Show simple item record

Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart

dc.contributor.authorMickelson, Judith K.en_US
dc.contributor.authorSimpson, Paul J.en_US
dc.contributor.authorLucchesi, Benedict Roberten_US
dc.date.accessioned2006-04-07T20:51:26Z
dc.date.available2006-04-07T20:51:26Z
dc.date.issued1989-04en_US
dc.identifier.citationMickelson, Judith K., Simpson, Paul J., Lucchesi, Benedict R. (1989/04)."Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart." Journal of Molecular and Cellular Cardiology 21(4): 393-405. <http://hdl.handle.net/2027.42/27996>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6WK6-4C547GX-GD/2/fafd2f710bf9acc40620d98897585720en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/27996
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2746660&dopt=citationen_US
dc.description.abstractInteractions between platelets with injured vascular endothelium contribute to thrombotic occlusion. A murine monoclonal antibody [7E3 F(ab')2] to the platelet GPIIb/IIIa receptor complex was used to inhibit platelet aggregation in an experimental model of coronary artery thrombosis. Prevention of thrombotic occlusion by 7E3 F(ab')2 (0.8 mg/kg bolus i.v.) was studied in dogs with direct current induced intimal injury (100 [mu]A for 5 h) and critical stenosis of the left circumflex coronary artery (LCCA). Baseline LCCA blood flow (CBF) was similar in 7E3 F(ab')2 and control groups, but decreased in the controls [24 +/- 2 ml/min to 0 +/- 0 ml/min, n = 13 (mean +/-)] due to thrombotic occlusion in each case (time to thrombosis 136 +/- 15 min). In the group treated with 7E3 F(ab')2, CBF did not change significantly (27 +/- 3 ml/min to 22 +/- 3 ml/min, n = 6) and thrombotic occlusion did not occur during the 5-h observation period in which intimal injury was produced in the LCCA (P 2 treatment (2.2 +/- 0.7 vs. 0 +/- 0, P 2 (P ex vivo, before the administration of the test agents, platelets from both groups of dogs aggregated in response to ADP and arachidonic acid. However, after treatment, the ex vivo aggregation of platelets from 7E3 F(ab')2 animals was inhibited whereas platelets from the control animals continued to aggregate ex vivo throughout the period of the experimental protocol (P 111indium showed accumulation of radio-activity within the thrombus and upon the vascular endothelium which was less in 7E3 F(ab')2 treated dogs as compared to the control group (P 2 did not affect hemodynamic values or the circulating platelet count during the experimental protocol. In conclusion, antibody to platelet GPIIb/IIIa receptors: (1) prevented thrombotic LCCA occlusion, (2) inhibited ex vivo platelet aggregation, (3) minimized platelet deposition on injured vascular endothelium and within formed thrombi, and (4) stabilized CBF during 5 h of continuous direct currrent induced intimal injury of the LCCA.en_US
dc.format.extent3066292 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleAntiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine hearten_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine (Cardiology), The University of Michigan Medical School, Ann Arbor, MI 48109-0626, USA; Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI 48109-0626, USA.en_US
dc.contributor.affiliationumDepartment of Internal Medicine (Cardiology), The University of Michigan Medical School, Ann Arbor, MI 48109-0626, USA; Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI 48109-0626, USA.en_US
dc.contributor.affiliationumDepartment of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI 48109-0626, USA; Department of Internal Medicine (Cardiology), The University of Michigan Medical School, Ann Arbor, MI 48109-0626, USA.en_US
dc.identifier.pmid2746660en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/27996/1/0000431.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/0022-2828(89)90650-0en_US
dc.identifier.sourceJournal of Molecular and Cellular Cardiologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.